Lindbrook Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Lindbrook Capital’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-52	Closed	-$499	–	2971
2024 Q4	$499	Buy	+52	New	+$271	﹤0.01%	2624
2022 Q1	–	Sell	-101	Closed	-$1K	–	2640
2021 Q4	$1K	Buy	+101	New	+$688	﹤0.01%	2027

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Lindbrook Capital's PSTX Position: Q1 2025 in Review

Lindbrook Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 52 shares — an estimated $499 sold.

Lindbrook Capital first reported a position in PSTX in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Lindbrook Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Lindbrook Capital sold 52 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $499.
Lindbrook Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
Lindbrook Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $1K in Q4 2021.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.